Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Table 1

Updated phase III randomised trials on dose escalation for prostate cancer. All results are statistically significant, except those marked with n.s.

		Median FU (yrs)	Dose (Gy)	Benefit bDFS (%)	Toxicity; GI (%)	Toxicity; GU (%)
MD Anderson
Kuban et al. 2008	301	8.7	70 versus 78	59 versus 78	13 versus 26	13 versus 8
MGH
Michalski et al. 2015	1499	7	70.2 versus 79.2	57 versus 74	16 versus 22	10 versus 15
Dutch trial
Heemsbergen et al. 2014	669	9.1	68 versus 78	61 versus 69	25 versus 35	40 versus 41
Royal Masden
Dearnaley et al. 2014	843	10	64 versus 74	43 versus 55	24 versus 33	8 versus 11
GETUG
Beckendorf et al. 2011	306	5.1	70 versus 80	68 versus 76.5	14 versus 19.5	10 versus 17.5

bDFS: biochemical disease-free survival. n.s.: not significant.